Augmented numbers of regulatory T cells contribute to the overall immunosuppression in tumor patients. Interleukin-2 has been widely used in the clinics in anticancer therapy, yet evidence has accumulated that the major drawback, limiting clinical efficacy, is the expansion of regulatory T cells, which aggravates immunosuppression.
No takes yet. Share an insight, caveat, or question.
Marc Beyer (2012) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: